Literature DB >> 9042970

Review article: irritable bowel syndrome.

M Camilleri1, M G Choi.   

Abstract

Irritable bowel syndrome is a disease that can be diagnosed positively on the basis of an established series of criteria and limited exclusion of organic disease. It is the most common disease diagnosed by gastroenterologists and affects about 20% of all people at any one time. Symptoms fluctuate, and the overall prevalence rate is relatively constant in Western communities. Ten per cent of patients present to their physicians; the illness has a large economic impact on health-care utilization and absenteeism. Irritable bowel syndrome is a biopsychosocial disorder in which three major mechanisms interact: psychosocial factors; altered motility; and/or sensory function of the intestine. Management of patients is based on positive diagnosis of the symptom complex, limited exclusion of underlying organic disease and institution of a therapeutic trial. If patient symptoms are intractable, further investigations are needed to exclude significant motility or other disorders. Symptomatic treatment includes fibre for constipation, loperamide for diarrhoea and low-dose antidepressants or infrequent use of antispasmodics for pain; novel pharmacological agents, psychotherapy and hypnotherapy are being evaluated.

Entities:  

Mesh:

Year:  1997        PMID: 9042970     DOI: 10.1046/j.1365-2036.1997.84256000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  48 in total

Review 1.  Memory in the enteric nervous system.

Authors:  J B Furness; N Clerc; W A Kunze
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

2.  Irritable Bowel Syndrome.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

3.  Could gastrointestinal disorders differ in two close but divergent social environments?

Authors:  Ewa Grodzinsky; Claes Hallert; Tomas Faresjö; Elisabet Bergfors; Ashild Olsen Faresjö
Journal:  Int J Health Geogr       Date:  2012-02-06       Impact factor: 3.918

4.  Prevalence, impact and attitudes toward lower gastrointestinal dysmotility and sensory symptoms, and their treatment in Canada: A descriptive study.

Authors:  Richard H Hunt; Surinder Dhaliwal; Gervais Tougas; Carmen Pedro; Jean-Francois Labbé; Heidi Paul; Michael Ennamorato
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

5.  Meal induced rectosigmoid tone modification: a low caloric meal accurately separates functional and organic gastrointestinal disease patients.

Authors:  M Di Stefano; E Miceli; A Missanelli; S Mazzocchi; G R Corazza
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

6.  Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome.

Authors:  Jeffrey M Lackner; James Jaccard; Laurie Keefer; Darren M Brenner; Rebecca S Firth; Gregory D Gudleski; Frank A Hamilton; Leonard A Katz; Susan S Krasner; Chang-Xing Ma; Christopher D Radziwon; Michael D Sitrin
Journal:  Gastroenterology       Date:  2018-04-25       Impact factor: 22.682

Review 7.  New therapies for functional bowel diseases.

Authors:  B Coulie; M Camilleri
Journal:  Curr Gastroenterol Rep       Date:  2000-10

Review 8.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

9.  Abnormalities of left colonic motility in ambulant nonconstipated patients with irritable bowel syndrome.

Authors:  C H M Clemens; M Samsom; G P Van Berge Henegouwen; A J P M Smout
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

10.  Development of colorectal sensitization is associated with increased eosinophils and mast cells in dextran sulfate sodium-treated rats.

Authors:  J M Tobin; L M D Delbridge; R Di Nicolantonio; P Bhathal
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.